D. Michael Olive and Joseph O’Connor
With the end of the antibiotic era looming, alternative antimicrobial agents are desperately needed. Lytic bacteriophage specific for a variety of bacteria have been used for almost 100 years to successfully treat serious infections. Here we make the case for pursuing formal regulatory approvals for the use of bacteriophage as therapeutic antimicrobial agents.
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu